Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
about
Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical CancerUse of rodents as models of human diseasesCurrent prospects for RNA interference-based therapiesInduction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells.Gene Silencing and Activation of Human Papillomavirus 18 Is Modulated by Sense Promoter Associated RNA in Bidirectionally Transcribed Long Control Region.E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest ChinaTargeted treatments for cervical cancer: a review.HPV-Based Screening, Triage, Treatment, and Followup Strategies in the Management of Cervical Intraepithelial Neoplasia.Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo.Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis.The small splice variant of HPV16 E6, E6, reduces tumor formation in cervical carcinoma xenograftsHuman papillomavirus promotes esophageal squamous cell carcinoma by regulating DNA methylation and expression of HLA-DQB1.Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA.Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability.MiR-520b as a novel molecular target for suppressing stemness phenotype of head-neck cancer by inhibiting CD44.Grand challenges in modulating the immune response with RNAi nanomedicines.Targeting HPV-infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine.
P2860
Q26799484-E9E9238F-63CD-411E-A6D5-24C41EEB3A7FQ26822856-F0AC94F5-925D-4F0C-ADFF-989C5E25BFB1Q28235733-5231FA08-620B-41BA-B0EA-497138A8FA23Q33656171-386FC1CF-81C9-4520-A874-DF415780F27BQ35654387-6C002607-65CC-4FF7-B3C4-DA399FB3EA3BQ36264936-54D5AC45-8284-4EB9-A28D-76EEAEC52308Q36384032-AD607213-3E34-4225-BD61-EA68FB7F49B5Q36830943-B9B838B6-9F7F-452C-AD44-87937BE900A0Q37478104-7DE53033-D12B-4F3B-AD87-EEE7842719C9Q37579334-F4C16343-39A6-429A-98DC-1351585627FAQ37598781-5E26C5C0-383B-4B82-91AD-E4CCC59143F6Q39073903-B4036644-7D89-46C6-9111-2CAC1E9FD12BQ39180977-5E802C0A-BA39-4383-BB0C-80D4AB338D11Q39476902-296E5B46-9403-4A6E-9C79-4A3D2116C642Q42259492-7787CB33-4FA0-4E8F-A582-C0B4801CB6B0Q47578379-100B2C22-672B-4D3A-B95A-AD1B99200C56Q55038951-97424BD2-63EC-4BDA-90C1-E0916B472C30
P2860
Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Highly potent and specific siR ...... PV18-infected cervical cancers
@ast
Highly potent and specific siR ...... PV18-infected cervical cancers
@en
Highly potent and specific siR ...... PV18-infected cervical cancers
@nl
type
label
Highly potent and specific siR ...... PV18-infected cervical cancers
@ast
Highly potent and specific siR ...... PV18-infected cervical cancers
@en
Highly potent and specific siR ...... PV18-infected cervical cancers
@nl
prefLabel
Highly potent and specific siR ...... PV18-infected cervical cancers
@ast
Highly potent and specific siR ...... PV18-infected cervical cancers
@en
Highly potent and specific siR ...... PV18-infected cervical cancers
@nl
P2093
P2860
P356
P1433
P1476
Highly potent and specific siR ...... PV18-infected cervical cancers
@en
P2093
P2860
P2888
P304
P356
10.1038/CGT.2010.38
P577
2010-10-01T00:00:00Z